Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target
Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry
Read more
Mind Medicine
MindMed Declares Q2 2021 Financials: US$193.9 Million Total Assets, US$35.6 Million Net Loss
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced Thursday night its interim financial results for Q2 2021.
Read more
MindMed Starts Clinical Trial For Intravenous DMT
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of Phase 1 clinical trial on
Read more
Psychedelics: The Eight Capital Primer
Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read more
Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles
It seems that after selling $24.7 million in company stock, JR Rahn is looking to step down from Mind Medicine
Read more
Mind Medicine Sees CEO Sell $24.7 Million In Company Stock
It appears that uplisting to the Nasdaq is good for business. Or, at least for liquidity, as per insider action
Read more
MindMed’s Mescaline Study Approved For Clinical Trial
MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have
Read more
MindMed Launches Psychedelic-Based Pain Treatment Project
Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched Project Angie. The project is
Read more
MindMed To Begin Trading On The Nasdaq April 27
MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning announced that it has been
Read more
Mind Medicine Boasts Current Cash Position Of US$161 Million
Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that the firm is pre-revenue, the
Read more